Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease - Aix-Marseille Université Access content directly
Journal Articles Journal of Clinical Endocrinology and Metabolism Year : 2022

Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease

Thomas Walter
Louis de Mestier
Antony Kelly
  • Function : Author
Ghoufrane Tlili
  • Function : Author
Sophie Giraud
  • Function : Author
Marie-Odile North
  • Function : Author
Bernard Goichot
  • Function : Author
Anderson Loundou
Alessio Imperiale
  • Function : Author
David Taïeb


Context Despite the growing evidence of the clinical value of somatostatin receptor (SSTR) positron emission tomography (PET) in the evaluation of neuroendocrine tumors (NETs), its role remains to be clarified at different time points in the journey of patients with multiple endocrine neoplasia type 1 (MEN1). The rarity of the disease is however a significant impediment to prospective clinical trials. Objective The goals of the study were to assess the indications and value of SSTR PET/computed tomography (CT) in patients with MEN1. Methods We retrospectively included patients from 7 French expert centers for whom data on SSTR PET/CT and morphological imaging performed at the same period were available. Detection rates of PET study were analyzed. Results One hundred and 8 patients were included. SSTR PET/CT was performed at screening (n = 33), staging (n = 34), restaging (n = 37), and for peptide receptor targeted radiotherapy selection (n = 4). PET detected positive pancreatic lesions in 91% of cases at screening, with results comparable with magnetic resonance imaging but superior to CT (P = .049). Metastases (mostly lymph node [LN]) were present at the screening phase in 28% of cases, possibly due to the suboptimal value of screening morphological imaging in the assessment of nodal metastases and/or a long delay between imaging studies. SSTR PET/CT was considered superior or complementary to the reference standard in the assessment of LN or distant metastases in the vast majority of cases and regardless of the clinical scenario. Conclusion This study shows the potential added value of SSTR PET in the assessment of MEN1-associated NETs and provides great impetus toward its implementation in the evaluation of patients with MEN1.
Fichier principal
Vignette du fichier
Men1_20211024_JCEM.pdf (419.64 Ko) Télécharger le fichier
Figure1.jpg (339.13 Ko) Télécharger le fichier
Figure2.jpg (141.52 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)

Dates and versions

hal-03662789 , version 1 (04-04-2023)



Clément Mennetrey, Maëlle Le Bras, Aurélie Bando-Delaunay, Laure Al-Mansour, Magalie Haissaguerre, et al.. Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107 (5), pp.e2056-e2064. ⟨10.1210/clinem/dgab891⟩. ⟨hal-03662789⟩
144 View
28 Download



Gmail Facebook X LinkedIn More